Stereotactic body radiotherapy (SBRT) of lung tumors via the ring-mounted Halcyon Linac, a fast kilovoltage cone beam CT-guided treatment with coplanar geometry, a single energy 6MV flattening filter free (FFF) beam and volumetric modulated arc therapy (VMAT) is a fast, safe, and feasible treatment modality for selected lung cancer patients. Four-dimensional (4D) CT-based treatment plans were generated using advanced AcurosXB algorithm with heterogeneity corrections using an SBRT board and Halcyon couch insert. Halcyon VMAT-SBRT plans with stacked and staggered multileaf collimators produced highly conformal radiosurgical dose distribution to the target, lower intermediate dose spillage, and similar dose to adjacent organs at risks (OARs) compared to SBRT-dedicated highly conformal clinical noncoplanar Truebeam VMAT plans following the RTOG-0813 requirements. Due to low monitor units per fraction and less multileaf collimator (MLC) modulation, the Halcyon VMAT plan can deliver lung SBRT fractions with an overall treatment time of less than 15 min (for 50 Gy in five fractions), significantly improving patient comfort and clinic workflow. Higher pass rates of quality assurance results demonstrate a more accurate treatment delivery on Halcyon. We have implemented Halcyon for lung SBRT treatment in our clinic. We suggest others use Halcyon for lung SBRT treatments using abdominal compression or 4D CT-based treatment planning, thus expanding the access of curative ultra-hypofractionated treatments to other centers with only a Halcyon Linac. Clinical follow-up results for patients treated on Halcyon Linac with lung SBRT is ongoing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856490 | PMC |
| http://dx.doi.org/10.1002/acm2.13146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers.
BMC Cancer
January 2025
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Purpose: To evaluate the safety and efficacy of Helical Tomotherapy stereotactic body radiotherapy (HT-SBRT) in treating multiple primary lung cancers (MPLCs) and second primary lung cancer (SPLC).
Methods: From January 2010 to September 2023, 106 MPLCs and SPLC (T1-3N0M0) underwent HT-SBRT. The cumulative incidence for local recurrence (LR) was calculated using the competing risk approach and compared using Gray's test.
Validation of a Monte Carlo-based dose calculation engine including the 1.5 T magnetic field for independent dose-check in MRgRT.
Phys Med
January 2025
Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni 5, 37024 Negrar di Valpolicella, VR, Italy; University of Brescia, Brescia, Italy.
Purpose: Adaptive MRgRT by 1.5 T MR-linac requires independent verification of the plan-of-the-day by the primary TPS (Monaco) (M). Here we validated a Monte Carlo-based dose-check including the magnetostatic field, SciMoCa (S).
View Article and Find Full Text PDFAge Is Just a Number? A Retrospective Review of Cause of Death in Patients 85 Years and Over Receiving Lung Stereotactic Ablative Radiotherapy.
J Med Imaging Radiat Oncol
January 2025
Icon Cancer Centre Gold Coast University Hospital, Southport, Queensland, Australia.
Introduction: Patients aged > 85 years are under-represented in research that has established stereotactic body radiotherapy (SBRT) as the standard of care in early stage non-small cell lung cancer (NSCLC) not suitable for or refusing surgery. With an ageing population in Australia, it is important to assess SBRT and cause of death (COD) in elderly patients receiving curative intent lung SBRT.
Methods: This is a multi-centre retrospective review of eligible patients treated across Australia from 2016 to 2022 with curative intent lung SBRT for early stage primary NSCLC, and aged 85 years or over.
Enhancing patient engagement: the influence of an in-consult patient decision aid on shared decision-making for lung tumour radiation - protocol for the randomised trial 'SDM Lung SBRT'.
BMJ Open
January 2025
Department of Regional Health Research, University of Southern Denmark, Vejle, Denmark.
Introduction: Patient engagement is continuously being promoted by patients as well as politicians and healthcare professionals. One way of increasing patient engagement is by using shared decision-making (SDM), which is a joint effort of clinicians and patients making decisions together.When planning stereotactic body radiation therapy (SBRT) for a lung tumour located close to the thoracic wall, there are conflicting interests between (1) delivering the highest possible dose to obtain local tumour control and (2) reducing the dose to the thoracic wall to decrease the risk of chest wall pain and rib fractures following treatment.
View Article and Find Full Text PDFQuantitative evaluation of accumulated and planned dose deviations in patients undergoing gated and non-gated lung stereotactic body radiation therapy patients: a retrospective analysis.
Transl Lung Cancer Res
December 2024
Department of Radiation Oncology, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China.
Background: Stereotactic body radiation therapy (SBRT) is crucial for treating early-stage inoperable non-small cell lung cancer (NSCLC) due to its precision and high-dose delivery. This study aimed to investigate the dosimetric deviations in gated (GR) versus non-gated radiotherapy (NGR), analyzing the impact of tumor location, target volume, and tumor motion range on dose distribution accuracy.
Methods: Sixty patients treated with either gated (n=30) or non-gated (n=30) SBRT for early-stage NSCLC were retrospectively analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!